CLINICAL TRIALS PROFILE FOR TENIVAC
✉ Email this page to a colleague
All Clinical Trials for TENIVAC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02097849 ↗ | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | Completed | Biogen | Phase 2 | 2015-02-28 | Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T cell-dependent neoantigen response]. |
| NCT02193347 ↗ | IDH1 Peptide Vaccine for Recurrent Grade II Glioma | Active, not recruiting | Gary Archer Ph.D. | Phase 1 | 2016-01-28 | Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TENIVAC
Condition Name
Clinical Trial Locations for TENIVAC
Trials by Country
Clinical Trial Progress for TENIVAC
Clinical Trial Phase
Clinical Trial Sponsors for TENIVAC
Sponsor Name
